Price T Rowe Associates Inc Savara Inc Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Savara Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 38,432 shares of SVRA stock, worth $116,064. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,432

Previous 30,984 24.04%

Holding current value

$116,064

Previous $125,000 30.4%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.96 - $5.07 $29,494 - $37,761	7,448 Added 24.04%	38,432 $163,000
Q2 2024 Aug 14, 2024	SELL	$3.66 - $5.34 $9,911 - $14,460	-2,708 Reduced 8.04%	30,984 $125,000
Q1 2024 May 15, 2024	BUY	$4.19 - $5.59 $19,378 - $25,853	4,625 Added 15.91%	33,692 $168,000
Q4 2023 Feb 14, 2024	BUY	$3.18 - $4.9 $5,555 - $8,560	1,747 Added 6.39%	29,067 $137,000
Q3 2023 Nov 14, 2023	SELL	$2.97 - $3.88 $24,469 - $31,967	-8,239 Reduced 23.17%	27,320 $104,000
Q2 2023 Aug 14, 2023	BUY	$1.69 - $3.24 $11,152 - $21,380	6,599 Added 22.79%	35,559 $114,000
Q3 2022 Nov 14, 2022	BUY	$1.36 - $1.88 $8,432 - $11,656	6,200 Added 27.24%	28,960 $45,000
Q2 2022 Aug 15, 2022	BUY	$1.1 - $1.58 $990 - $1,422	900 Added 4.12%	22,760 $35,000
Q1 2022 May 16, 2022	BUY	$1.05 - $1.36 $4,830 - $6,256	4,600 Added 26.65%	21,860 $29,000
Q2 2021 Aug 16, 2021	SELL	$1.51 - $2.29 $2,631 - $3,991	-1,743 Reduced 9.17%	17,260 $29,000
Q1 2021 May 17, 2021	BUY	$1.17 - $2.33 $8,424 - $16,776	7,200 Added 61.0%	19,003 $40,000
Q4 2020 Feb 16, 2021	BUY	$1.0 - $1.47 $11,803 - $17,350	11,803 New	11,803 $14,000

Others Institutions Holding SVRA

# of Institutions

128

Shares Held

158M

Call Options Held

67.6K

Put Options Held

29.4K

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $344M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Savara Inc Transaction History